Related Experiment Video
Updated: Jun 5, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Pharmacotherapy for acute heart failure syndromes
James C Coons1, Molly McGraw, Srinivas Murali
1Department of Pharmacy, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, USA. jcoons@wpahs.org
Summary
Acute heart failure syndromes (AHFS) treatment guidelines emphasize diuretics and vasodilators for congestion, de-emphasizing inotropes. Early initiation of these therapies and optimizing oral medications improve patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute heart failure syndromes (AHFS) present with new-onset or worsening heart failure (HF) signs and symptoms requiring urgent treatment.
- Current clinical practice guidelines offer recommendations for managing hospitalized patients with HF.
Purpose of the Study:
- To review drug therapies for acute heart failure syndromes (AHFS).
- To incorporate clinical practice guideline recommendations for hospitalized heart failure (HF) patients.
Main Methods:
- Review of clinical practice guidelines from major cardiology societies.
- Analysis of drug therapies including diuretics, vasodilators, inotropes, and newer agents.
Main Results:
- Guidelines recommend vasodilators for pulmonary congestion unresponsive to diuretics.
- Early use of diuretics and vasodilators is linked to improved outcomes.
- Routine use of inotropes is de-emphasized.
- Initiation of evidence-based oral medications for long-term use is crucial during hospitalization.
Conclusions:
- Drug therapy for AHFS includes diuretics, vasodilators, morphine, ACE inhibitors, digoxin, inotropes, and vasopressin antagonists.
- Clinical practice guidelines facilitate the integration of evidence and standards of care for AHFS management.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...